Related Experiment Videos
[New thrombolytic agents in myocardial infarction]
Insights
New thrombolytic agents, including tissue plasminogen activator (t-PA) mutants like reteplase, are improving myocardial infarction treatment. Research also explores staphylokinase and anti-thrombotic combinations for better outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Myocardial infarction (MI) results from thrombotic coronary artery occlusion.
- Current thrombolytics improve outcomes but have limitations including incomplete arterial patency (50%), reocclusion (5-10%), and severe complications (0.5%).
Purpose of the Study:
- To review recent advances in the development of novel thrombolytic agents for myocardial infarction.
- To discuss the potential of new therapeutic strategies, including adjuvant anti-thrombotic treatments.
Main Methods:
- Review of recent scientific literature on thrombolytic agents.
- Analysis of clinical trial results for new thrombolytic agents and combination therapies.
Main Results:
- Development of tissue plasminogen activator (t-PA) mutants, such as reteplase (r-PA), TNK-t-PA, and lanoteplast, shows promise.
- Staphylokinase is under renewed investigation with initial clinical trial results reported.
- Adjuvant therapy with glycoprotein IIb/IIIa inhibitors and anti-thrombin agents is being explored.
Conclusions:
- Novel thrombolytic agents and combination therapies offer potential improvements over existing treatments for myocardial infarction.
- Further research is warranted to optimize thrombolytic strategies and mitigate associated risks.
Abstract:
Myocardial infarction is the result of thrombotic coronary artery occlusion. Although present-day thrombolytics have major value by increasing the frequency of reopening of arteries responsible for myocardial infarction, by preserving myocardial function and, thereby, significantly reduce mortality. Nevertheless, they are subject to the following limitations: 1) excellent arterial partency is only obtained in 50% of cases: 2) reocclusion occurs in 5 to 10% of cases; 3) severe complications such as cerebral haemorrhage are observed in about 0.5% of cases. Therefore, the search to improve thrombolytic agents is intense. This article reports the recent advances in concept and production of new thrombolytic agents. The most recent results concern the production of mutants of T-PA (tissue plasmogen activator). Of these mutants, the reteplase (r-PA) has already received authorization for its commercialisation. Other t-PA mutants under development (phase 3) include TNK-t-PA and lanoteplase. Over the last few years, there has been renewed interest in staphylokinase. The results of the initial clinical trials with this agent have also been reported. Paradoxically, the mode of action of thrombolytic agents has an inherent pro-thrombotic effect. This explains some of the interest for anti-thrombotic agents as an adjuvant treatment of thrombolysis. The initial results of the association of thrombolytics with new glycoprotein IIb/IIIa platelet inhibitors and anti-thrombin agents are reported.